Home Market Woodford-backed company’s share price bombs after failed drugs trial

Woodford-backed company’s share price bombs after failed drugs trial


A biotechnology company backed by investor Neil Woodford saw its share price fall off a cliff today after announcing the withdrawal of a new drug.

Prothena, which is nearly 29 per cent owned by a fund controlled by Woodford, saw its share price plunge by 70 per cent, wiping more than $1bn (£720m) from its market capitalisation.

The Irish-based Nasdaq-listed biotech business announced that it was discontinuing development of a drug to treat amyloidosis after examining test results.

The news is another blow for Woodford who saw his fund shrink by a fifth – £1.6bn – in the first three months of the year.

Read more: Woodford flagship flounders as fund falls by a fifth this year alone

Woodford said: “Despite the disappointment that we feel, that our investors will feel, and indeed the company feels more acutely, there is a lot of value in Prothena.”

He said that Prothena is a “much broader business” which has “multiple shots on goal” and a “technology platform that we think is extremely valuable”.

After launching in June 2014, Woodford's main fund last registered assets under management of less than £7bn in June 2015. They peaked in May 2017 at a mammoth £10.2bn.

Woodford has been on the wrong end of a number of poor trades in recent months, with big sell-offs in the likes of Provident Financial, Capita and the AA demolishing performance.

It has not all been doom and gloom for Woodford of late, with a Welsh biotechnology firm that he backs announcing it had treated its first UK cancer patient using proton beam technology earlier this month.


Please enter your comment!
Please enter your name here